What is CAMP4 Therapeutics?
CAMP4 Therapeutics operates as a pioneer in the biotechnology sector, specializing in the development of tissue-specific Gene Circuitry Maps. By deciphering the complex transcriptional machinery and signaling networks that govern cellular behavior, the company identifies novel therapeutic targets with unprecedented precision. Unlike traditional drug discovery models, CAMP4's platform enables the precise tuning of gene expression, offering a versatile engine for therapeutic development across diverse disease areas. This technological edge positions the firm as a critical player in the next generation of precision medicine, where the focus shifts from treating symptoms to correcting the underlying genetic drivers of pathology.
How much funding has CAMP4 Therapeutics raised?
CAMP4 Therapeutics has raised a total of $175M across 3 funding rounds:
Series A
$30M
Other Financing Round
$45M
Series B
$100M
Series A (2018): $30M with participation from Andreessen Horowitz, The Kraft Group, and Polaris Partners
Other Financing Round (2021): $45M led by Northpond Ventures, Andreessen Horowitz, The Kraft Group, 5AM Ventures, and Polaris Partners
Series B (2022): $100M supported by Andreessen Horowitz, The Kraft Group, 5AM Ventures, Polaris Partners, Gaingels, Northpond Ventures, and Enavate Sciences
Key Investors in CAMP4 Therapeutics
Andreessen Horowitz
A prominent venture capital firm based in Menlo Park, California, known for its extensive portfolio in both early-stage startups and established growth-stage technology and biotech companies.
5AM Ventures
A specialized life science venture capital firm that partners with founders to fund rigorous scientific research and bring transformative healthcare technologies to patients.
Polaris Partners
A venture capital firm with over two decades of experience, focusing on backing transformational companies within the biotech and healthcare sectors through deep operational and scientific collaboration.
What's next for CAMP4 Therapeutics?
With the successful closure of its latest financing round, CAMP4 Therapeutics is well-positioned to accelerate its pipeline development and expand its Gene Circuitry Map library. The strategic deployment of this capital will likely focus on scaling its discovery engine to identify new druggable targets, thereby broadening its therapeutic reach. As the company transitions into more advanced clinical stages, the focus will remain on validating its platform's efficacy in human models and establishing key partnerships to bring its innovative gene-regulation therapies to market. The firm's trajectory suggests a sustained commitment to transforming the landscape of genetic disease treatment through rigorous scientific innovation and strategic capital allocation.
See full CAMP4 Therapeutics company page
